Switching between infliximab biosimilars for IBD found safe
19 Jul 2021
bởiJairia Dela Cruz
In the treatment of inflammatory bowel disease (IBD), switching from one infliximab biosimilar to another does not significantly alter trough levels and disease activity, regardless of whether switching for the first or second time, as shown in a study. Likewise, there is no substantial difference noted in time to loss of response using clinically relevant definitions.
